Background. Apathy and impulsivity in Parkinson disease (PD) are associated with clinically significant behavioral disorders. Aim. To explore the phenomenology, distribution, and clinical correlates of these two behaviors. Methods. In PD participants ( ) without dementia we explored the distribution of measures of motivation and impulsivity using univariate methods. We then undertook factor analysis to define specific underlying dimensions of apathy and impulsivity. Regression models were developed to determine the associated demographic and clinical features of the derived dimensions. Results. The factor analysis of apathy (AES-C) revealed a two-factor solution: “cognitive-behavior” and “social indifference”. The factor analysis of impulsivity (BIS-11) revealed a five-factor solution: “inattention”; “impetuosity”; “personal security”; “planning”; and “future orientation”. Apathy was significantly associated with: age, age of motor symptom onset (positive correlation), disease stage, motor symptom severity, and depression. Impulsivity was significantly associated with: age of motor symptom onset (negative correlation), gambling and anxiety scores, and motor complications. We observed an overlap of apathy and impulsivity in some participants. Conclusion. In PD, apathy and impulsivity have specific phenomenological profiles and are associated with particular clinical phenotypes. In spite of this, there is some overlap of behaviors which may suggests common aspects in the pathology underlying motivation and reward processes. 1. Introduction The non-motor symptoms of Parkinson disease (PD) are increasingly recognised as being important factors in determining the quality of life of people living with the condition [1]. The psychiatric and cognitive aspects of these non-motor symptoms are generally well recognized; however, the behavioural syndromes of apathy and impulse control disorders (ICDs), and the symptoms that comprise them, have received much less attention and are less well understood. Apathy is a multidimensional construct and has been defined as a lack of goal-directed behavior, cognition, or emotion [2]. It can be assessed using rating scales such as the Apathy Evaluation Scale (AES-C) [3], which is one of the most widely used in PD. Impulsivity can be defined as “actions that are poorly conceived, prematurely expressed, unduly risky, or inappropriate to the situation and that often result in undesirable outcomes” [4]. Impulsivity or “impulsiveness” may underlie a broad range of psychiatric disorders in addition to the ICDs, including personality
References
[1]
P. Martinez-Martin, C. Rodriguez-Blazquez, M. M. Kurtis, and K. R. Chaudhuri, “The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease,” Movement Disorders, vol. 26, no. 3, pp. 399–406, 2011.
[2]
R. Levy and B. Dubois, “Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits,” Cerebral Cortex, vol. 16, no. 7, pp. 916–928, 2006.
[3]
R. S. Marin, R. C. Biedrzycki, and S. Firinciogullari, “Reliability and validity of the apathy evaluation scale,” Psychiatry Research, vol. 38, no. 2, pp. 143–162, 1991.
[4]
J. L. Evenden, “Varieties of impulsivity,” Psychopharmacology, vol. 146, no. 4, pp. 348–361, 1999.
[5]
J. H. Patton, M. S. Stanford, and E. S. Barratt, “Factor structure of the Barratt Impulsiveness Scale,” Journal of Clinical Psychology, vol. 51, no. 6, pp. 768–774, 1995.
[6]
M. F. Folstein, S. E. Folstein, and P. R. McHugh, “‘Mini mental state’. A practical method for grading the cognitive state of patients for the clinician,” Journal of Psychiatric Research, vol. 12, no. 3, pp. 189–198, 1975.
[7]
A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, “Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases,” Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 3, pp. 181–184, 1992.
[8]
M. Emre, D. Aarsland, R. Brown et al., “Clinical diagnostic criteria for dementia associated with Parkinson's disease,” Movement Disorders, vol. 22, no. 12, pp. 1689–1707, 2007.
[9]
B. Dubois, D. Burn, C. Goetz et al., “Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society Task Force,” Movement Disorders, vol. 22, no. 16, pp. 2314–2324, 2007.
[10]
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC, USA, 4th edition, 2000.
[11]
I. Leroi, D. J. Ahearn, M. Andrews, K. R. Mcdonald, E. J. Byrne, and A. Burns, “Behavioural disorders, disability and quality of life in Parkinson's disease,” Age and Ageing, vol. 40, no. 5, Article ID afr078, pp. 614–621, 2011.
[12]
S. E. Starkstein, H. S. Mayberg, T. J. Preziosi, P. Andrezejewski, R. Leiguarda, and R. G. Robinson, “Reliability, validity, and clinical correlates of apathy in Parkinson's disease,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 4, no. 2, pp. 134–139, 1992.
[13]
A. F. G. Leentjens, K. Dujardin, L. Marsh et al., “Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations,” Movement Disorders, vol. 23, no. 14, pp. 2004–2014, 2008.
[14]
S. Fahn, R. L. Elton, and UPDRS Development Committee, “Unified Parkinson’s disease rating scale,” in Recent Developments in Parkinson’s Disease, S. Fahn, C. D. Marsden, D. B. Calne, and M. Goldstein, Eds., pp. 153–163, Macmillan, Florham Park, NJ, USA, 1987.
[15]
M. M. Hoehn and M. D. Yahr, “Parkinsonism: onset, progression and mortality,” Neurology, vol. 17, no. 5, pp. 427–442, 1967.
[16]
C. L. Tomlinson, R. Stowe, S. Patel, C. Rick, R. Gray, and C. E. Clarke, “Systematic review of levodopa dose equivalency reporting in Parkinson's disease,” Movement Disorders, vol. 25, no. 15, pp. 2649–2653, 2010.
[17]
A. S. Zigmond and R. P. Snaith, “The hospital anxiety and depression scale,” Acta Psychiatrica Scandinavica, vol. 67, no. 6, pp. 361–370, 1983.
[18]
J. L. Cummings, M. Mega, K. Gray, S. Rosenberg-Thompson, D. A. Carusi, and J. Gornbein, “The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia,” Neurology, vol. 44, no. 12, pp. 2308–2314, 1994.
[19]
H. R. Lesieur and S. B. Blume, “The South Oaks Gambling Screen (SOGS): a new instrument for the identification of Pathological gamblers,” American Journal of Psychiatry, vol. 144, no. 9, pp. 1184–1188, 1987.
[20]
I. Leroi, M. Andrews, K. McDonald et al., “Apathy and impulse control disorders in Parkinson's disease: a direct comparison,” Parkinsonism and Related Disorders, vol. 18, no. 2, pp. 198–203, 2012.
[21]
A. Field, Discovering Statistics Using SPSS, Sage, 2nd edition, 2005.
[22]
G. C. Pluck and R. G. Brown, “Apathy in Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 73, no. 6, pp. 636–642, 2002.
[23]
P. Sockeel, K. Dujardin, D. Devos, C. Denève, A. Destée, and L. Defebvre, “The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 5, pp. 579–584, 2006.
[24]
K. Dujardin, P. Sockeel, D. Devos et al., “Characteristics of apathy in Parkinson's disease,” Movement Disorders, vol. 22, no. 6, pp. 778–784, 2007.
[25]
K. N. Kirby and J. C. Finch, “The hierarchical structure of self-reported impulsivity,” Personality and Individual Differences, vol. 48, no. 6, pp. 704–713, 2010.
[26]
P. Robert, C. U. Onyike, A. F. G. Leentjens et al., “Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders,” European Psychiatry, vol. 24, no. 2, pp. 98–104, 2009.
[27]
A. Bowirrat and M. Oscar-Berman, “Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome,” American Journal of Medical Genetics - Neuropsychiatric Genetics, vol. 132, no. 1, pp. 29–37, 2005.
[28]
D. E. Comings and K. Blum, “Reward deficiency syndrome: genetic aspects of behavioral disorders,” Progress in Brain Research, vol. 126, pp. 325–341, 2000.
[29]
T. Van Eimeren, G. Pellecchia, R. Cilia et al., “Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD,” Neurology, vol. 75, no. 19, pp. 1711–1716, 2010.
[30]
V. Voon, J. Gao, C. Brezing et al., “Dopamine agonists and risk: impulse control disorders in Parkinson's; Disease,” Brain, vol. 134, no. 5, pp. 1438–1446, 2011.
[31]
C. R. Cloninger, “A systematic method for clinical description and classification of personality variants: a proposal,” Archives of General Psychiatry, vol. 44, no. 6, pp. 573–588, 1987.
[32]
J. Pagonabarraga, C. García-Sánchez, G. Llebaria, B. Pascual-Sedano, A. Gironell, and J. Kulisevsky, “Controlled study of decision-making and cognitive impairment in Parkinson's disease,” Movement Disorders, vol. 22, no. 10, pp. 1430–1435, 2007.
[33]
V. Voon, M. Sohr, A. E. Lang et al., “Impulse control disorders in parkinson disease: a multicenter case-control study,” Annals of Neurology, vol. 69, no. 6, pp. 986–996, 2011.
[34]
M. J. Frank, J. Samanta, A. A. Moustafa, and S. J. Sherman, “Hold your horses: impulsivity, deep brain stimulation, and medication in Parkinsonism,” Science, vol. 318, no. 5854, pp. 1309–1312, 2007.
[35]
R. Cools, L. Altamirano, and M. D'Esposito, “Reversal learning in Parkinson's disease depends on medication status and outcome valence,” Neuropsychologia, vol. 44, no. 10, pp. 1663–1673, 2006.
[36]
M. J. Frank and R. C. O'Reilly, “A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol,” Behavioral Neuroscience, vol. 120, no. 3, pp. 497–517, 2006.
[37]
B. H. Schott, L. Niehaus, B. C. Wittmann et al., “Ageing and early-stage Parkinson's disease affect separable neural mechanisms of mesolimbic reward processing,” Brain, vol. 130, no. 9, pp. 2412–2424, 2007.
[38]
A. M. Landes, S. D. Sperry, M. E. Strauss, and D. S. Geldmacher, “Apathy in Alzheimer's disease,” Journal of the American Geriatrics Society, vol. 49, no. 12, pp. 1700–1707, 2001.
[39]
M. Benoit, S. Clairet, P. M. Koulibaly, J. Darcourt, and P. H. Robert, “Brain perfusion correlates of the Apathy Inventory dimensions of Alzheimer's disease,” International Journal of Geriatric Psychiatry, vol. 19, no. 9, pp. 864–869, 2004.
[40]
D. J. Zgaljardic, J. C. Borod, N. S. Foldi et al., “Relationship between self-reported apathy and executive dysfunction in nondemented patients with Parkinson disease,” Cognitive and Behavioral Neurology, vol. 20, no. 3, pp. 184–192, 2007.
